Methylselenocysteine treatment leads to diselenide formation in human cancer cells: evidence from X-ray absorption spectroscopy studies
Date
2012
Authors
Weekley, C.
Aitken, J.
Musgrave, I.
Harris, H.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Biochemistry, 2012; 51(3):736-738
Statement of Responsibility
Claire M. Weekley, Jade B. Aitken, Ian F. Musgrave, and Hugh H. Harris
Conference Name
Abstract
The selenoamino acids methylselenocysteine (MeSeCys) and selenomethionine (SeMet) have disparate efficacies as anticancer agents. Herein, we use X-ray absorption spectroscopy to determine the chemical form of selenium in human neuroblastoma cells. Cells treated with MeSeCys contain a significant diselenide component, which is absent from SeMet-treated cells and suggests that metabolites of MeSeCys are capable of altering the redox status of the cells. The differences in the speciation of Se in the selenoamino acid-treated cells may provide insight into the differing anticancer activities of MeSeCys and SeMet.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright © 2012 American Chemical Society